Terminated
OBSERVATIONAL
NCT02698384
Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The study aims to evaluate the biochemical and clinical effectiveness on symptoms and tumor size of a monotherapy with Lanreotide 120mg in acromegalic subjects, to describe criteria for starting alternative strategies, and to describe the modalities and the global effectiveness of alternative strategies.
Primary Outcomes
Measure:
Percentage of subjects who achieve a safe concentration of random Growth Hormone (GH) (≤2.5 ng/mL) and normal age and sex-matched Insulin-like Growth Factor-1 (IGF-1) concentration of the monotherapy phase.
TimeFrame:
Month 5
Description:
Trial Information
NCT ID
NCT02698384
Status
Terminated
Study Type
OBSERVATIONAL
Sponsor
Ipsen
Last Updated
December 15, 2025